Abstract
Background: IgA nephropathy (IgAN) is characterized by mesangial deposition of polymeric IgA1 (pIgA1), yet the pathogeneic mechanism remains unresolved. In the present study, we examined the glycosylation profile of differently charged IgA1 from IgAN patients. The binding characteristics of these IgA1 fractions to cultured human mesangial cells (HMC) and hepatoma cell lines (HepG2) were studied. Methods: Differently charged IgA1 were isolated by ion exchange chromatography. The glycosylation profile in the carbohydrate moieties of these differently charged IgA1 was analyzed by galactose (Gal)-, galactose-acetylgalactosamine (Gal-GalNAc)-, or sialic acid-specific enzyme-linked lectin binding assays (ELLA). The binding characteristic of these IgA1 to HMC was examined by flow cytometry and competitive binding assay. Results: Anionic pIgA from IgAN patients showed less reactivity in (Gal)- and (Gal-GalNAc)-specific ELLA (p < 0.01). There was higher reactivity for anionic pIgA1 in α(2,6)-linked sialic acid-specific ELLA (p < 0.01). Anionic pIgA1 from IgAN patients exhibited increased binding to cultured HMC and the binding was significantly reduced after neuraminidase treatment (p < 0.05). In contrast, anionic pIgA1 from IgAN patients bound less to cultured HepG2 cells and the binding was enhanced following neuraminidase treatment (p < 0.05). Conclusions: We demonstrated an unusual glycosylation and sialylation pattern of anionic pIgA1 in IgAN which may have an important effect on its pathogenesis.
Journal Section:
Original Paper
References
1.
Lai KN, Mac-Moune Lai F, Li PK, Chan KW, Au TC, Tong KL: The clinicopathological characteristics of IgA nephropathy in Hong Kong. Pathology 1988;20:15–19.
[PubMed]
2.
Kim YS, Moon JI, Jeong HJ, Kim MS, Kim SI, Choi KH, Lee HY, Han DS, Park K: Live donor renal allograft in end-stage renal failure patients from immunoglobulin A nephropathy. Transplantation 2001;71:233–238.
[PubMed]
3.
Kerr MA, Mazengera RL, Stewart WW: Structure and function of immunoglobulin A receptors on phagocytic cells. Biochem Soc Trans 1990;18:215–217.
[PubMed]
4.
Field MC, Dwek RA, Edge CJ, Rademacher TW: O-linked oligosaccharides from human serum immunoglobulin A1. Biochem Soc Trans 1989;17:1034–1035.
[PubMed]
5.
Hiki Y, Horii A, Iwase H, Tanaka A, Toda Y, Hotta K, Kobayashi Y: O-linked oligosaccharide on IgA1 hinge region in IgA nephropathy. Fundamental study for precise structure and possible role. Contrib Nephrol 1995;111:73–84.
[PubMed]
6.
Mattu TS, Pleass RJ, Willis AC, Kilian M, Wormald MR, Lellouch AC, Rudd PM, Woof JM, Dwek RA: The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fc alpha receptor interactions. J Biol Chem 1998;273:2260–2272.
[PubMed]
7.
Monteiro RC, Halbwachs-Mecarelli L, Berger J, Lesavre P: Characteristics of eluted IgA in primary IgA nephropathy. Contrib Nephrol 1984;40:107–111.
[PubMed]
8.
Isaacs KL, Miller F: Role of antigen size and charge in immune complex glomerulonephritis. Lab Invest 1982;47:198–205.
[PubMed]
9.
Gallo GR, Caulin-Glaser T, Emancipator SN, Lamm ME: Nephritogenicity and differential distribution of glomerular immune complexes related to immunogen charge. Lab Invest 1983;48:353–362.
[PubMed]
10.
Gauthier VJ, Striker GE, Mannik M: Glomerular localization of preformed immune complexes prepared with anionic antibodies or with cationic antigens. Lab Invest 1984;50:636–644.
[PubMed]
11.
Monteiro RC, Chevailler A, Noel LH, Lesavre P: Serum IgA preferentially binds to cationic polypeptides in IgA nephropathy. Clin Exp Immunol 1988;73:300–306.
[PubMed]
12.
Sakagami Y, Nakajima M, Takagawa K, Ueda T, Akazawa H, Maruhashi Y, Shimoyama H, Kamitsuji H, Yoshioka A: Analysis of glomerular anionic charge status in children with IgA nephropathy using confocal laser scanning microscopy. Nephron Clin Pract 2004;96:c96–c104.
[PubMed]
13.
Dueymes M, Baharaki D, Cledes J, Pennec YL, Youinou P: IgA glycosylation and disease. Adv Exp Med Biol 1995;376:217–220.
[PubMed]
14.
Leung JC, Poon PY, Lai KN: Increased sialylation of polymeric immunoglobulin A1: mechanism of selective glomerular deposition in immunoglobulin A nephropathy? J Lab Clin Med 1999;133:152–160.
[PubMed]
15.
Leung JC, Tang SC, Chan DT, Lui SL, Lai KN: Increased sialylation of polymeric lambda-IgA1 in patients with IgA nephropathy. J Clin Lab Anal 2002;16:11–19.
[PubMed]
16.
Leung JC, Tang SC, Lam MF, Chan TM, Lai KN: Charge-dependent binding of polymeric IgA1 to human mesangial cells in IgA nephropathy. Kidney Int 2001;59:277–285.
[PubMed]
17.
To WY, Leung JC, Lai KN: Identification and characterization of human serum alpha2-HS glycoprotein as a jacalin-bound protein. Biochim Biophys Acta 1995;1249:58–64.
[PubMed]
18.
Lai KN, Tang SC, Guh JY, Chuang TD, Lam MF, Chan LY, Tsang AW, Leung JC: Polymeric IgA1 from patients with IgA nephropathy upregulates transforming growth factor-beta synthesis and signal transduction in human mesangial cells via the renin-angiotensin system. J Am Soc Nephrol 2003;14:3127–3137.
[PubMed]
19.
Allen AC, Bailey EM, Barratt J, Buck KS, Feehally J: Analysis of IgA1 O-glycans in IgA nephropathy by fluorophore-assisted carbohydrate electrophoresis. J Am Soc Nephrol 1999;10:1763–1771.
[PubMed]
20.
Hiki Y, Tanaka A, Kokubo T, Iwase H, Nishikido J, Hotta K, Kobayashi Y: Analyses of IgA1 hinge glycopeptides in IgA nephropathy by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Am Soc Nephrol 1998;9:577–582.
[PubMed]
21.
Mestecky J, Hashim OH, Tomana M: Alterations in the IgA carbohydrate chains influence the cellular distribution of IgA1. Contrib Nephrol 1995;111:66–72.
[PubMed]
22.
Tomana M, Julian BA, Waldo FB, Kulhavy R, Mestecky J: IgA nephropathy. A disease of incomplete IgA 1 glycosylation? Adv Exp Med Biol 1995;376:221.
[PubMed]
23.
Xu LX, Zhao MH: Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy. Kidney Int 2005;68:167–172.
[PubMed]
24.
Amore A, Cirina P, Conti G, Brusa P, Peruzzi L, Coppo R: Glycosylation of circulating IgA in patients with IgA nephropathy modulates proliferation and apoptosis of mesangial cells. J Am Soc Nephrol 2001;12:1862–1871.
[PubMed]
25.
Tomana M, Matousovic K, Julian BA, Radl J, Konecny K, Mestecky J: Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int 1997;52:509–516.
[PubMed]
26.
Tomana M, Novak J, Julian BA, Matousovic K, Konecny K, Mestecky J: Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 1999;104:73–81.
[PubMed]
27.
Wang Y, Zhao MH, Zhang YK, Li XM, Wang HY: Binding capacity and pathophysiological effects of IgA1 from patients with IgA nephropathy on human glomerular mesangial cells. Clin Exp Immunol 2004;136:168–175.
[PubMed]
28.
Xu LX, Yan Y, Zhang JJ, Zhang Y, Zhao MH: The glycans deficiencies of macromolecular IgA1 is a contributory factor of variable pathological phenotypes of IgA nephropathy. Clin Exp Immunol 2005;142:569–575.
[PubMed]
29.
Chui SH, Lewis WH, Lam CW, Lai KN: Analysis of charge of kappa and lambda chain-containing serum immunoglobulin A by immunoblotting and densitometry. Clin Biochem 1993;26:97–100.
[PubMed]
30.
Harada T, Hobby P, Courteau M, Knight JF, Williams DG: Charge distribution of plasma IgA in IgA nephropathy. Clin Exp Immunol 1989;77:211–214.
[PubMed]
31.
Monteiro RC, Halbwachs-Mecarelli L, Roque-Barreira MC, Noel LH, Berger J, Lesavre P: Charge and size of mesangial IgA in IgA nephropathy. Kidney Int 1985;28:666–671.
[PubMed]
32.
Allen AC, Bailey EM, Brenchley PE, Buck KS, Barratt J, Feehally J: Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int 2001;60:969–973.
[PubMed]
33.
Hiki Y, Odani H, Takahashi M, Yasuda Y, Nishimoto A, Iwase H, Shinzato T, Kobayashi Y, Maeda K: Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 2001;59:1077–1085.
[PubMed]
34.
Mestecky J, Russell MW, Jackson S, Brown TA: The human IgA system: a reassessment. Clin Immunol Immunopathol 1986;40:105–114.
[PubMed]
35.
Tomana M, Niedermeier W, Mestecky J, Skvaril F: The differences in carbohydrate composition between the subclasses of IgA immunoglobulins. Immunochemistry 1976;13:325–328.
[PubMed]
36.
Tomana M, Kulhavy R, Mestecky J: Receptor-mediated binding and uptake of immunoglobulin A by human liver. Gastroenterology 1988;94:762–770.
[PubMed]
© 2007 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2007
You do not currently have access to this content.
